HPRA Drug Safety Newsletter Edition 108
Download:
hpra-drug-safety-newsletter-edition-108.pdf
262 KB
The latest edition of the HPRA Drug Safety Newsletter (Edition 108) includes important updates to support the safe and appropriate use of the following medicines:
Topiramate - commencement of EU review regarding potential risk of neurodevelopmental disorders in children exposed in utero
Mavenclad (cladribine) - new liver monitoring requirements to minimise risk of serious liver injury
Pregabalin - expanded warning regarding drug dependence and withdrawal symptoms
Product information updates recommended by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC)
« Back